Biom’Up

Biom’Up®, a European-based medical device firm focused on collagen-based absorbable medical products for biosurgery, recently sought to obtain its first Class III Investigational Device Exemption (IDE) and Premarket Approval (PMA) in the United States.

Biom’Up achieved record-breaking results of $17M in cost savings and 23 months in accelerated timelines.

Biom’Up Achieves Record-Breaking Medical Device Development Timelines with NAMSA’s MRO® Approach